News Article

AI is changing the economics of the outsourced pharma-services market.

But will it hurt CROs by making drug development more successful, or create a much larger market by getting more drugs through to expensive later-stage trials?

In a detailed new analysis for Healthcare Today, Candesic managing partner Dr Leonid Shapiro examines what the rise of AI-discovered drugs could mean for CROs, CDMOs and other outsourced pharma-services businesses.

Drawing on clinical success-rate data, market sizing and detailed scenario analysis, the piece explores where the additional demand could land, which parts of the market face pressure, and how pharma companies’ response to higher success rates could shape the outcome.

The analysis is supported by a series of graphs and data-driven charts, making this a useful read for anyone assessing the impact of AI across the pharma-services value chain.

📖 Read the full analysis: CLICK HERE

Want to know more about Candesic’s extensive work and research in this area? Email [email protected], or reach out to Leonid on LinkedIn.